Search

Your search keyword '"Bodini, G."' showing total 338 results
Start Over Author "Bodini, G."
338 results on '"Bodini, G."'

1. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., Bezzio, C., Bossa, F., Privitera, A.C., Marchi, S., Roselli, J., Mazzuoli, S., Geccherle, A., Soriano, A., Principi, M.B., Viola, A., Sarpi, L., Cappello, M., D'Incà, R., Mastronardi, M., Bodini, G., Guerra, M., Benedetti, A., Romano, M., Cicala, M., Di Sabatino, A., Scaldaferri, F., De Rosa, T., Giardino, A.M., Germano, V., Orlando, A., and Armuzzi, A.

Published
2024
Full Text
View/download PDF

2. Efficient laser-driven proton acceleration from a petawatt contrast-enhanced second harmonic mixed-glass laser system.

Author

Gonzalez-Izquierdo, B., Fischer, P., Touati, M., Hartmann, J., Speicher, M., Scutelnic, V., Rivas, D. E., Bodini, G., Fazzini, A., Günther, M. M., Härle, A. K., Kenney, K., Schork, E., Bruce, S., Spinks, M., Quevedo, H. J., Helal, A., Medina, M., Gaul, E., and Ruhl, H.

Subjects
PARTICLE acceleration, PROTON beams, ION beams, PLASMA acceleration, INTERIM governments, FEMTOSECOND pulses, LASER pulses
Abstract

Efficient laser-driven plasma acceleration of ion beams requires precision control of the target–plasma profile, which is crucial to optimize the laser energy transfer. Along the laser propagation direction, this can be achieved by tailoring the temporal structure of the laser pulse. We show for the first time that frequency-doubling of a short pulse (hundreds-femtosecond range) petawatt-class mixed-glass laser system, which results in temporal intensity contrast enhancement, enables surface and volumetric laser–energy coupling, and the acceleration of proton beams from few-nanometer-thick foil targets. Experimentally, maximum ion energies and laser-to-proton energy conversion efficiencies were found to be both maximized at optimum laser and target conditions manifested when the normalized target density nearly equalizes the normalized laser vector potential, which is in agreement with theory and simulations. These signatures are recognized as a unique indication of the interaction between ultra-intense laser pulses with high temporal intensity contrast and ultra-thin nanometer-scale targets. Transverse modulations of accelerated proton beams in the form of bubble- and ring-like structures measured in the thinnest targets provide additional evidence of volumetric laser-driven particle acceleration regimes and transitional features in ultra-thin foil targets specific to laser–plasma interactions characterized by a high temporal intensity contrast. These results open avenues in the generation of high contrast laser pulses from short-pulse-femtosecond petawatt mixed-glass laser systems and demonstrate the feasibility of this technique for applications requiring high laser intensity contrast with high efficiency. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY

Author

Viola, A., primary, Ventimiglia, M., additional, Sparacino, A., additional, D'Antonio, E., additional, Orlando, A., additional, De Vivo, S., additional, Pugliese, D., additional, Varca, S., additional, Scaldaferri, F., additional, Ribaldone, D.G., additional, Armandi, A., additional, Balestrieri, P., additional, Castiglione, F., additional, Savarino, E.V., additional, Cappello, M., additional, Viganò, C., additional, Mocci, G., additional, Allocca, M., additional, Principi, M.B., additional, Soriano, A., additional, Onali, S., additional, Bodini, G., additional, Riguccio, G., additional, Festa, S., additional, Bertani, L., additional, Checchin, D., additional, Caprioli, F., additional, and Fries, W., additional

Published
2024
Full Text
View/download PDF

5. P965 Ulcerative proctitis treated with biologics: is it too hard to treat?

Author

Bertani, L, primary, Tricò, D, additional, Barberio, B, additional, Bretto, E, additional, Ceccarelli, L, additional, Calabrese, F, additional, Pasta, A, additional, Bertin, L, additional, Fabiana, Z, additional, Maniero, D, additional, Frara, S, additional, De Bernardi, A, additional, Bodini, G, additional, Ribaldone, D G, additional, Costa, F, additional, and Savarino, E V, additional

Published
2024
Full Text
View/download PDF

6. P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy

Author

Bertani, L, primary, Tricò, D, additional, Barberio, B, additional, Vernero, M, additional, Bretto, E, additional, Ceccarelli, L, additional, Pardi, V, additional, Calabrese, F, additional, Pasta, A, additional, Bertin, L, additional, Fabiana, Z, additional, Semprucci, G, additional, Bodini, G, additional, Ribaldone, D G, additional, Savarino, E V, additional, and Costa, F, additional

Published
2024
Full Text
View/download PDF

9. P544 Ustekinumab safety and effectiveness in ulcerative colitis patients: results from a large real-life study

Author

Mocci, G, primary, Scaldaferri, F, additional, Pugliese, D, additional, Savarino, E, additional, Bodini, G, additional, Cuomo, A, additional, Donnarumma, L, additional, Maconi, G, additional, Cataletti, G, additional, Rodino, S, additional, Sebkova, L, additional, Ferronato, A, additional, Gaiani, F, additional, Marzo, M, additional, Luppino, I, additional, Paese, P, additional, Elisei, W, additional, Monterubbianesi, R, additional, Faggiani, R, additional, Napolitano, D, additional, Grossi, L, additional, Serio, M, additional, Scarcelli, A, additional, Lorenzetti, R, additional, Allegretta, L, additional, Rocco, G, additional, Zampaletta, C, additional, Bolognini, L, additional, Meucci, C, additional, Colucci, R, additional, Tonti, P, additional, Della Valle, N, additional, Piga, R, additional, Forti, G, additional, Onidi, F M, additional, Usai Satta, P, additional, Picchio, M, additional, Papa, A, additional, and Tursi, A, additional

Published
2024
Full Text
View/download PDF

11. Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data

Author

Marabotto E, Ziola S, Savarino V, Giannini EG, Furnari M, Bodini G, Zingone F, Ghisa M, Barberio B, Zentilin P, and Savarino E

Subjects
gastric ulcer, p-cab, adverse events, peptic disease, ppi, h2-receptor antagonists, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Elisa Marabotto, 1 Sebastiano Ziola, 1 Vincenzo Savarino, 1 Edoardo Giovanni Giannini, 1 Manuele Furnari, 1 Giorgia Bodini, 1 Fabiana Zingone, 2 Matteo Ghisa, 2 Brigida Barberio, 2 Patrizia Zentilin, 1 Edoardo Savarino 2 1Division of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, ItalyCorrespondence: Elisa MarabottoDivision of Gastroenterology, Department of Internal Medicine, University of Genoa, Viale Benedetto XV, 6, Genova 16132, ItalyTel/Fax +390103538923Email elisa.marabotto@unige.itAbstract: Potassium-competitive acid blockers (P-CABs), such as vonoprazan, represent a novel and heterogeneous class of drugs that competitively block the potassium binding site of gastric H+/K+ ATPase, thus potentially overcoming the limitations of proton-pump inhibitors. Different studies evaluated the efficacy of vonoprazan versus proton-pump inhibitors (PPIs) for the treatment of acid-related disorders, and, therefore, P-CABs present the same indications of PPIs: gastroesophageal reflux disease, gastric and duodenal ulcer healing, management of upper gastrointestinal bleeding, non-steroidal anti-inflammatory drug (NSAID)-associated ulcers and Helicobacter pylori eradication therapy. The aim of this review was to evaluate the role of vonoprazan for the treatment of peptic ulcer disease (PUD) and the management of gastric ulcer occurring after endoscopic submucosal dissection (ESD). Indeed, vonoprazan (at the dose of both 10 and 20mg) showed similar results to PPIs in patients taking long-term NSAIDs, in the absence of severe adverse effects, and provided a more rapid and effective treatment of ulcers induced by ESD. However, studies in medical literature are heterogeneous, mainly performed with a retrospective design, and often carried out in Japan only. For these reasons, further prospective, randomized studies are warranted in order to help physicians, patients, and policymakers regarding the use of vonoprazan in clinical practice.Keywords: gastric ulcer, P-CAB, adverse events, peptic disease, PPI, H2-receptor antagonists

Published
2020

12. Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: Data of a national study (ESCAPE-IBD)

Author

Principi, M, Macaluso, F, Todeschini, A, Facciotti, F, Contaldo, A, Castiglione, F, Nardone, O, Spagnuolo, R, Doldo, P, Riguccio, G, Conforti, F, Vigano, C, Ascolani, M, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Caprioli, F, Mannino, M, Rizzo, G, Orlando, A, Principi M., Macaluso F. S., Todeschini A., Facciotti F., Contaldo A., Castiglione F., Nardone O. M., Spagnuolo R., Doldo P., Riguccio G., Conforti F. S., Vigano C., Ascolani M., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Caprioli F., Mannino M., Rizzo G., Orlando A., Principi, M, Macaluso, F, Todeschini, A, Facciotti, F, Contaldo, A, Castiglione, F, Nardone, O, Spagnuolo, R, Doldo, P, Riguccio, G, Conforti, F, Vigano, C, Ascolani, M, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Caprioli, F, Mannino, M, Rizzo, G, Orlando, A, Principi M., Macaluso F. S., Todeschini A., Facciotti F., Contaldo A., Castiglione F., Nardone O. M., Spagnuolo R., Doldo P., Riguccio G., Conforti F. S., Vigano C., Ascolani M., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Caprioli F., Mannino M., Rizzo G., and Orlando A.

Abstract

Background and aims The purpose of this study was to present data on the safety of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in a cohort of inflammatory bowel disease (IBD) patients of an ongoing multicenter study (ESCAPE-IBD) sponsored by the Italian Group for the study of Inflammatory Bowel Disease (ClinicalTrials.gov Identifier: NCT04769258). Methods Anti-SARS-CoV-2 vaccination was administrated to 809 IBD patients. Interviews were conducted to report adverse events related to vaccination. Of these 809, 346 patients were surveyed on the pandemic burden and the main reason for hesitancy in coronavirus disease 2019 vaccination. The chi-square test was used to compare categorical variables. Logistic regression was used to assess the relationship between disease-related characteristics and the onset of adverse events. Results About 45% of patients had at least one side effect, following the first dose (10%), the second (15%), and both doses (19%). All the adverse events were mild and lasted only a few days. Logistic regression analysis revealed that female sex (P < 0.001), younger age (P = 0.001), seroconversion (P = 0.002), and comorbidity (P < 0.001) were significantly associated with adverse events. The survey showed that the main concerns were the possibility of adverse event (33%). Almost all patients (99%) felt safer having been vaccinated at their IBD reference center. Conclusion The vaccine reactions experienced in IBD patients were mostly self-limited. We found high acceptance and good safety of SARS-CoV-2 vaccination in our cohort.

Published
2023

13. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study

Author

Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Mannino, M, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Casa, A, Comberlato, M, Conforti, F, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, Rizzuto, G, Macaluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Mannino M., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Casa A., Comberlato M., Conforti F. S., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., Rizzuto G., Macaluso, F, Principi, M, Facciotti, F, Contaldo, A, Todeschini, A, Saibeni, S, Bezzio, C, Castiglione, F, Nardone, O, Spagnuolo, R, Fantini, M, Riguccio, G, Caprioli, F, Vigano, C, Felice, C, Fiorino, G, Correale, C, Bodini, G, Milla, M, Scardino, G, Vernero, M, Desideri, F, Mannino, M, Rizzo, G, Orlando, A, Amato, A, Ascolani, M, Calabrese, G, Casa, A, Comberlato, M, Conforti, F, De Bona, M, Demarzo, M, Doldo, P, Dragoni, G, Furfaro, F, Mulinacci, G, Olmo, O, O'Sed, N, Paba, S, Radice, S, Renna, S, Ribaldone, D, Rizzuto, G, Macaluso F. S., Principi M., Facciotti F., Contaldo A., Todeschini A., Saibeni S., Bezzio C., Castiglione F., Nardone O. M., Spagnuolo R., Fantini M. C., Riguccio G., Caprioli F., Vigano C., Felice C., Fiorino G., Correale C., Bodini G., Milla M., Scardino G., Vernero M., Desideri F., Mannino M., Rizzo G., Orlando A., Amato A., Ascolani M., Calabrese G., Casa A., Comberlato M., Conforti F. S., De Bona M., Demarzo M. G., Doldo P., Dragoni G., Furfaro F., Mulinacci G., Olmo O., O'Sed N. P., Paba S., Radice S., Renna S., Ribaldone D. G., and Rizzuto G.

Abstract

Background: Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy. Aims: To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) Methods: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs). Results: 1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reported for most IBD patients, even if with a lesser rate compared with HCs (92.1% vs. 97.9%; p<0.001). HCs had higher antibody concentrations (median OD 8.72 [IQR 5.2-14-2]) compared to the whole cohort of IBD patients (median OD 1.54 [IQR 0.8-3.6]; p<0.001) and the subgroup of IBD patients (n=280) without any treatment or on aminosalicylates only (median OD 1.72 [IQR 1.0–4.1]; p<0.001). Conclusions: Although most IBD patients showed seropositivity after COVID-19 vaccines, the magnitude of the humoral response was significantly lower than in HCs. Differently from other studies, these findings seem to be mostly unrelated to the use of immune-modifying treatments (ClinicalTrials.govID:NCT04769258).

Published
2023

14. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study

Author

Saibeni, S., primary, Bezzio, C., additional, Bossa, F., additional, Privitera, A.C., additional, Marchi, S., additional, Roselli, J., additional, Mazzuoli, S., additional, Geccherle, A., additional, Soriano, A., additional, Principi, M.B., additional, Viola, A., additional, Sarpi, L., additional, Cappello, M., additional, D'Incà, R., additional, Mastronardi, M., additional, Bodini, G., additional, Guerra, M., additional, Benedetti, A., additional, Romano, M., additional, Cicala, M., additional, Sabatino, A. Di, additional, Scaldaferri, F., additional, De Rosa, T., additional, Giardino, A.M., additional, Germano, V., additional, Orlando, A., additional, and Armuzzi, A., additional

Published
2023
Full Text
View/download PDF

15. OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY

Author

Macaluso, F.S., primary, Principi, M., additional, Facciotti, F., additional, Contaldo, A., additional, Todeschini, A., additional, Saibeni, S., additional, Bezzio, C., additional, Castiglione, F., additional, Nardone, O., additional, Spagnuolo, R., additional, Fantini, M., additional, Riguccio, G., additional, Conforti, F., additional, Caprioli, F., additional, Vigano, C., additional, Felice, C., additional, Fiorino, G., additional, Correale, C., additional, Bodini, G., additional, Milla, M., additional, Scardino, G., additional, Vernero, M., additional, Desideri, F., additional, Bossa, F., additional, Guerra, M., additional, Ventimiglia, M., additional, Mannino, M., additional, Rizzo, G., additional, and Orlando, A., additional

Published
2023
Full Text
View/download PDF

18. Optimal management of constipation associated with irritable bowel syndrome

Author

Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Marabotto E, Moscatelli A, Del Nero L, Savarino E, Giannini EG, and Savarino V

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Manuele Furnari,1 Nicola de Bortoli,2 Irene Martinucci,2 Giorgia Bodini,1 Matteo Revelli,3 Elisa Marabotto,1 Alessandro Moscatelli,1 Lorenzo Del Nero,1 Edoardo Savarino,4 Edoardo G Giannini,1 Vincenzo Savarino1 1Division of Gastroenterology, Department of Internal Medicine, University of Genoa, Genoa, Italy; 2Division of Gastroenterology, Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy; 3Department of Radiology, San Bartolomeo Hospital, Sarzana, Italy; 4Division of Gastroenterology, Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy Abstract: Irritable bowel syndrome (IBS) is a common chronic functional disorder of the gastrointestinal tract, meanly characterized by recurrent abdominal pain or discomfort and altered bowel habit. It is a complex disorder involving biological, environmental, and psychosocial factors. The diagnosis is achieved according to the Rome III criteria provided that organic causes have been excluded. Although IBS does not constitute a life-threatening condition, it has a remarkable prevalence and profoundly reduces the quality of life with burdening socioeconomic costs. One of the principal concerns about IBS is the lack of effective therapeutic options. Up to 40% of patients are not satisfied with any available medications, especially those suffering from chronic constipation. A correct management of IBS with constipation should evolve through a global approach focused on the patient, starting with careful history taking in order to assess the presence of organic diseases that might trigger the disorder. Therefore, the second step is to examine lifestyle, dietary habits, and psychological status. On these bases, a step-up management of disease is recommended: from fiber and bulking agents, to osmotic laxative drugs, to new molecules like lubiprostone and linaclotide. Although new promising tools for relief of bowel-movement-related symptoms are being discovered, a dedicated doctor–patient relationship still seems to be the key for success. Keywords: IBS, functional gastrointestinal disorders, laxatives

Published
2015

19. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

20. PC.01.4 REDUCED IMMUNE RESPONSE INDUCED BY TWO DOSES OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IG-IBD STUDY

Author

Macaluso, F.S., primary, Principi, M., additional, Facciotti, F., additional, Contaldo, A., additional, Todeschini, A., additional, Saibeni, S., additional, Bezzio, C., additional, Castiglione, F., additional, Nardone, O.M., additional, Spagnuolo, R., additional, Doldo, P., additional, Fantini, M.C., additional, Paba, S., additional, Riguccio, G., additional, Conforti, F.S., additional, Viganò, C., additional, Ascolani, M., additional, Bodini, G., additional, Milla, M., additional, Scardina, G., additional, Vernero, M., additional, Desideri, F., additional, Mannino, M., additional, Rizzo, G., additional, Caprioli, F.A., additional, and Orlando, A., additional

Published
2022
Full Text
View/download PDF

21. T.06.8 COMPARATIVE OBJECTIVE EFFECTIVENESS OF VEDOLIZUMAB AND USTEKINUMAB IN A REAL-LIFE COHORT OF ACTIVE CROHN’S DISEASE PATIENTS FAILURE TO TNF INHIBITORS

Author

Onali, S., primary, Pugliese, D., additional, Caprioli, F.A., additional, Orlando, A., additional, Biancone, L., additional, Nardone, O.M., additional, Imperatore, N., additional, Fiorino, G., additional, Cappello, M., additional, Viola, A., additional, Principi, M.B., additional, Bezzio, C., additional, Aratari, A., additional, Carparelli, S., additional, Mancuso, F., additional, Grossi, L., additional, Bodini, G., additional, Ribaldone, D., additional, Mocci, G., additional, Favale, A., additional, Grova, M., additional, Scucchi, L., additional, Segato, S., additional, Fries, W., additional, Castiglione, F., additional, Armuzzi, A., additional, and Fantini, M.C., additional

Published
2022
Full Text
View/download PDF

22. OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)

Author

Todeschini, A., primary, Contaldo, A., additional, Macaluso, F.S., additional, Facciotti, F., additional, Castiglione, F., additional, Nardone, O.M., additional, Spagnuolo, R., additional, Doldo, P., additional, Riguccio, G., additional, Conforti, F.S., additional, Viganò, C., additional, Ascolani, M., additional, Bodini, G., additional, Milla, M., additional, Scardino, G., additional, Vernero, M., additional, Desideri, F., additional, Mannino, M., additional, Rizzo, G., additional, Di Leo, A., additional, Orlando, A., additional, and Principi, M., additional

Published
2022
Full Text
View/download PDF

24. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy

Author

Vitello, A, Grova, M, Pugliese, D, Rizzello, F, Lanzarotto, F, Lavagna, A, Caccaro, R, Cappello, M, Viola, A, Ribaldone, Dg, Principi, M, Stasi, E, Scribano, Ml, Maida, M, Soriano, A, Bezzio, C, Bodini, G, Mocciaro, F, Privitera, Ac, Simondi, D, Giuffrida, E, D'Incà, R, Ricci, C, Gionchetti, P, Armuzzi, A, Orlando, A, Daperno, M, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Vitello A., Grova M., Pugliese D., Rizzello F., Lanzarotto F., Lavagna A., Caccaro R., Cappello M., Viola A., Ribaldone D.G., Principi M., Stasi E., Scribano M.L., Maida M., Soriano A., Bezzio C., Bodini G., Mocciaro F., Privitera A.C., Simondi D., Giuffrida E., D'Inca R., Ricci C., Gionchetti P., Armuzzi A., Orlando A., and Daperno M.

Subjects
musculoskeletal diseases, Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Effectiveness, Young Adult, Internal medicine, Adalimumab, Medicine, Humans, Adverse effect, skin and connective tissue diseases, Colectomy, Aged, Retrospective Studies, Real-world evidence, Hepatology, business.industry, Gastroenterology, Effectivene, Retrospective cohort study, Induction Chemotherapy, Middle Aged, medicine.disease, Ulcerative colitis, Discontinuation, Clinical Practice, Treatment Outcome, Italy, Safety, Concomitant, Colitis, Ulcerative, Female, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract

Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (44.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion Adalimumab is safe and effective for the treatment of ulcerative colitis.

Published
2021

25. IBD and Covid-19 in Italy: comparisons between first and second pandemic wave

Author

Bezzio, C., Costa, S., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Bossa, F., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Alessandro Armuzzi, Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Fiorino, G., Vernero, M., and Saibeni, S.

Subjects
covid-19, inflammatory bowel disease, outcomes
Published
2022

26. P268 IBD and Covid-19 in italy: comparisons between first and second pandemic wave

Author

Bezzio, C, primary, Costa, S, additional, Armuzzi, A, additional, Furfaro, F, additional, Ardizzone, S, additional, Milla, M, additional, Bossa, F, additional, Orlando, A, additional, Caprioli, F A, additional, Castiglione, F, additional, Viganò, C, additional, Ribaldone, D G, additional, Zingone, F, additional, Monterubbianesi, R, additional, Imperatore, N, additional, Festa, S, additional, Daperno, M, additional, Scucchi, L, additional, Ferronato, A, additional, Pastorelli, L, additional, Balestrieri, P, additional, Ricci, C, additional, Cappello, M, additional, Felice, C, additional, Coppini, F, additional, Alvisi, P, additional, Gerardi, V, additional, Variola, A, additional, Mazzuoli, S, additional, Lenti, M V, additional, Alessandro, S, additional, Buda, A, additional, Micheli, F, additional, Ciardo, V, additional, Casella, G, additional, Viscido, A, additional, Bodini, G, additional, Fiorino, G, additional, Vernero, M, additional, and Saibeni, S, additional

Published
2022
Full Text
View/download PDF

27. P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors

Author

Onali, S, primary, Pugliese, D, additional, Caprioli, F A, additional, Orlando, A, additional, Biancone, L, additional, Nardone, O M, additional, Imperatore, N, additional, Fiorino, G, additional, Cappello, M, additional, Viola, A, additional, Principi, M B, additional, Bezzio, C, additional, Aratari, A, additional, Carparelli, S, additional, Mazzuoli, S, additional, Manguso, F, additional, Grossi, L, additional, Bodini, G, additional, Ribaldone, D, additional, Mocci, G, additional, Minerba, L, additional, Favale, A, additional, Grova, M, additional, Scucchi, L, additional, Segato, S, additional, Fries, W, additional, Castiglione, F, additional, Armuzzi, A, additional, and Fantini, M C, additional

Published
2022
Full Text
View/download PDF

31. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV 2 infection: an IG-IBD study

Author

Bezzio, C., Armuzzi, A., Furfaro, F., Ardizzone, S., Milla, M., Carparelli, S., Orlando, A., Caprioli, F. A., Castiglione, F., Vigano, C., Ribaldone, D. G., Zingone, F., Monterubbianesi, R., Imperatore, N., Festa, S., Daperno, M., Scucchi, L., Ferronato, A., Pastorelli, L., Balestrieri, P., Ricci, C., Cappello, M., Felice, C., Fiorino, G., Saibeni, S., Coppini, F., Alvisi, P., Gerardi, V., Variola, A., Mazzuoli, S., Lenti, M. V., Pugliese, D., Allocca, M., Ferretti, F., Roselli, J., Bossa, F., Giuliano, A., Piazza, N., Manes, G., Sartini, A., Buda, A., Micheli, F., Ciardo, V., Casella, G., Viscido, A., Bodini, G., Casini, V., Soriano, A., Amato, A., Grossi, L., Onali, S., Rottoli, M., Spagnuolo, R., Baroni, S., Cortelezzi, C. C., Baldoni, M., Vernero, M., Scaldaferri, F., Maconi, G., Guarino, A. D., Palermo, A., D'Inca, R., Scribano, M. L., Biancone, L., Carrozza, L., Ascolani, M., Costa, F., Di Sabatino, A., Zammarchi, I., Gottin, M., Conforti, F. S., Bezzio, Cristina, Armuzzi, Alessandro, Furfaro, Federica, Ardizzone, Sandro, Milla, Monica, Carparelli, Sonia, Orlando, Ambrogio, Caprioli, Flavio Andrea, Castiglione, Fabiana, Viganò, Chiara, Ribaldone, Davide Giuseppe, Zingone, Fabiana, Monterubbianesi, Rita, Imperatore, Nicola, Festa, Stefano, Daperno, Marco, Scucchi, Ludovica, Ferronato, Antonio, Pastorelli, Luca, Balestrieri, Paola, Ricci, Chiara, Cappello, Maria, Felice, Carla, Fiorino, Gionata, Saibeni, Simone, and Francesca Coppini, Patrizia Alvisi, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Daniela Pugliese, Mariangela Allocca, Francesca Ferretti, Jenny Roselli, Fabrizio Bossa, Alessandra Giuliano, Nicole Piazza, Gianpiero Manes, Alessandro Sartini, Andrea Buda, Federica Micheli, Valeria Ciardo, Giovanni Casella, Angelo Viscido, Giorgia Bodini, Valentina Casini, Alessandra Soriano, Arnaldo Amato, Laurino Grossi, Sara Onali, Matteo Rottoli, Rocco Spagnuolo, Stefania Baroni, Claudio Cortelezzi, Monia Baldoni, Marta Vernero, Franco Scaldaferri, Giovanni Maconi, Alessia Dalila Guarino, Andrea Palermo, Renata D'Incà, Maria Lia Scribano, Livia Biancone, Lucio Carrozza, Marta Ascolani, Francesco Costa, Antonio Di Sabatino, Irene Zammarchi, Matteo Gottin, Francesco Simone Conforti

Subjects
medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, IBD, Population, Ulcerative, Disease, Lower risk, Asymptomatic, Inflammatory bowel disease, Aged, Humans, SARS-CoV-2, Tumor Necrosis Factor Inhibitors, COVID-19, Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases, IBD Treatments and Sars‐cov‐2 Infection, Internal medicine, medicine, biologics, Pharmacology (medical), education, therapy, education.field_of_study, Hepatology, business.industry, INFLAMMATORY BOWEL DISEASE, Gastroenterology, medicine.disease, Colitis, Ulcerative colitis, Pneumonia, Original Article, medicine.symptom, business, Cohort study
Abstract

Summary Background Older age and comorbidities are the main risk factors for adverse COVID‐19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. Aims To assess risk factors for adverse outcomes of COVID‐19 in IBD patients and use the identified risk factors to build risk indices. Methods Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. Results Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS‐CoV‐2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID‐19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune‐mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID‐19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID‐19 outcomes, but anti‐TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID‐19 in CD. Conclusion The course of COVID‐19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID‐19 re‐vaccination or for therapies for SARS‐CoV‐2 infection., The course of COVID‐19 in patients with IBD patients is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID‐19 outcomes. IBD medications do not pose additional risks.

Published
2021

32. Two years Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

Author

Pugliese, D, Privitera, G, Rogai, F, Variola, A, Viola, A, Laterza, L, Privitera, Ac, Allocca, M, Bossa, F, Cappello, M, Daperno, M, Lorenzon, G, Mazzuoli, S, Principi, M, Sablich, R, Moser, L, Ferronato, A, Traini, S, Tapete, G, Bodini, G, Di Girolamo, M, Grossi, L, Mocci, G, Ricci, C, Saibeni, S, Festa, S, Spagnuolo, R, Cortelezzi, Cc, Mocciaro, F, Rizzello, F, Armuzzi, A, and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD

Subjects
remission, naïve, persistence, Golimumab, ulcerative colitis
Published
2021

34. OC.12.6 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1

Author

Bergamaschi, G., primary, Lenti, M.V., additional, Giuffrida, P., additional, Soriano, S., additional, D'Incà, R., additional, Astegiano, M., additional, Aronico, N., additional, Fries, W., additional, Rizzello, F., additional, Ciacci, C., additional, Bossa, F., additional, Orlando, A., additional, Ghigliazza, G., additional, Castiglione, F., additional, Milla, M., additional, Nardelli, S., additional, Principi, M.B., additional, Scribano, M.L., additional, Ricci, C., additional, Mazzucco, D., additional, Riegler, G., additional, Bassotti, G., additional, Buda, A., additional, Neri, M., additional, Bodini, G., additional, Monica, F., additional, Manca, A., additional, Villa, E., additional, Comberlato, M., additional, Saibeni, S., additional, Bezzio, C., additional, Sidoli, L., additional, Cannatelli, R., additional, Neve, V., additional, Vernia, P., additional, Pieraccini, A., additional, Testa, A., additional, Mengoli, C., additional, Rizzuto, G., additional, Fontana, R., additional, Iovino, P., additional, Valerii, C., additional, Pinto Vraca, T., additional, Ponzo, E., additional, Caccaro, R., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2020
Full Text
View/download PDF

35. T04.01.9 IMPACT OF ULCERATIVE COLITIS AND ITS ASSOCIATED DISEASE BURDEN ON ITALIAN PATIENTS: THE FIRST-YEAR ANALYSIS OF THE ICONIC STUDY

Author

Orlando, A., primary, Daperno, M., additional, Maconi, G., additional, Biancone, L., additional, Scribano, M.L., additional, Principi, M., additional, Burrelli Scotti, G., additional, Bodini, G., additional, Ribaldone, D.G., additional, Gemignani, L., additional, Gualberti, G., additional, and Fiorino, G., additional

Published
2020
Full Text
View/download PDF

38. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis

Author

Bertani, L., Bodini, G., Mumolo, M. G., de Bortoli, N., Ceccarelli, L., Frazzoni, L., Tapete, G., Albano, E., Plaz Torres, M. C., Bellini, M., Savarino, E., Savarino, V., Marchi, S., Costa, F., and Bellini, Massimo

Subjects
Adult, Male, medicine.medical_specialty, Multivariate analysis, Physiology, medicine.medical_treatment, Corticosteroid treatment, Colonoscopy, Disease, Gastroenterology, Young Adult, Adrenal Cortex Hormones, Recurrence, Internal medicine, medicine, Humans, Corticosteroids, Clinical relapses, Disease progression, Ulcerative colitis, Colectomy, Retrospective Studies, medicine.diagnostic_test, business.industry, Hepatology, Middle Aged, medicine.disease, Clinical relapses, Corticosteroids, Disease progression, Ulcerative colitis, Colitis, Ulcerative, Female, business, Follow-Up Studies
Abstract

Ulcerative colitis is a chronic relapsing disease usually treated with mesalamine. The need of steroid therapy at diagnosis is generally considered as a poor prognostic factor. The aim of our study was to assess whether patients treated with corticosteroids at diagnosis have more clinical relapses, disease progression, or an increased risk of colectomy during a 5-year follow-up. We retrospectively evaluated patients who had received diagnosis of ulcerative colitis with a 5-year follow-up. Relapse was defined as a worsening of symptoms requiring an increase in medical treatment. Progression of disease was defined as a proximal extension of mucosal involvement, comparing the colonoscopy performed 5 years after diagnosis with the first one. The need of corticosteroid treatment at diagnosis was correlated to number of relapses, disease progression, and colectomy rate. We included 230 patients, 116 of them (50%) treated with steroids at diagnosis. Multivariate analysis demonstrated that there is a strong correlation between corticosteroid use and number of relapses (p

Published
2019

39. Mediterranean diet and NAFLD: What we know and questions that still need to be answered

Author

Torres, M. C. P., Aghemo, A., Lleo, A., Bodini, G., Furnari, M., Marabotto, E., Miele, Luca, Giannini, E. G., Miele L. (ORCID:0000-0003-3464-0068), Torres, M. C. P., Aghemo, A., Lleo, A., Bodini, G., Furnari, M., Marabotto, E., Miele, Luca, Giannini, E. G., and Miele L. (ORCID:0000-0003-3464-0068)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is expected to become the leading cause of end-stage liver disease worldwide over the next few decades. In fact, NAFLD encompasses different clinical scenarios, from the simple accumulation of fat (steatosis) to steatohepatitis (NASH), NASH-cirrhosis, and cirrhosis complications. In this context, it is fundamental to pursue strategies aimed at both preventing the disease and reducing the progression of liver fibrosis once liver damage is already initiated. As of today, no pharmacological treatment has been approved for NAFLD/NASH, and the only recommended treatment of proven efficacy are life-style modifications, including diet and physical exercise pointing at weight loss of 5%–7%. Different dietetic approaches have been proposed in this setting, and in this review, we will discuss the evidence regarding the efficacy of the Mediterranean Diet as a treatment for NAFLD. In particular, we will report the effects on liver-related outcomes.

Published
2019

41. Prevalence of anaemia in Italian patients with inflammatory bowel disease: Preliminary results of the observational multi-centre IG-IBD study RIDART 1

Author

Giuffrida, P., Fries, W, Aronico, N., and D'Inca, R, Lenti, Mv, Ciacci, C, Cococcia, S, Bossa, F, Ghigliazza, G, Castiglione, F, Principi, Mb, Ricci, C, Mazzucco, D, Manetti, N, Scribano, Ml, Riegler, G, Bodini, G, Bassotti, G, Monica, F, Masotti, M, Vernia, P, Manca, A, Buda, A, Villa, E, Neri, M, Comberlato, M, Testa, A, Fontana, R, Iovino, P, Sturniolo, Gc, Corazza, Gr, and Di Sabatino, A.

Published
2018

42. PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1

Author

Bergamaschi, G, Giuffrida, P., Fries, W, Aronico, N., D'Inca, R, Lenti, Mv, Ciacci, C, Cococcia, S, Bossa, F, Ghigliazza, G, Castiglione, F, Principi, Mb, Ricci, C, Mazzucco, D, Milla, M, Pieraccini, A, Scribano, Ml, Riegler, G, Bodini, G, Bassotti, G, Monica, F, Masotti, M, Vernia, P, Manca, A, Buda, A, Villa, E, Neri, M, Comberlato, M, Testa, A, Soriano, S, Fontana, R, Iovino, P, Sturniolo, Gc, Corazza, Gr, and Di Sabatino, A.

Published
2018

43. P.07.22 HIGH RESOLUTION ANORECTAL MANOMETRY FOR DETERMINATION OF ANORECTAL FUNCTION IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION

Author

Gravina, A.G., primary, Volpe, M.C. Lanza, additional, Picascia, D., additional, Dallio, M., additional, Caprio, G.G., additional, Savarino, E., additional, Bodini, G., additional, Savarino, V., additional, Terrarcciano, G., additional, Federico, A., additional, Loguercio, C., additional, Docimo, L., additional, and Tolone, S., additional

Published
2019
Full Text
View/download PDF

44. OC.09.5 LONG TERM COLECTOMY RATE IN ACUTE SEVERE ULCERATIVE COLITIS. AN ITALIAN MULTICENTER IG-IBD STUDY

Author

Festa, S., primary, Scribano, M.L., additional, Pugliese, D., additional, Sarli, E., additional, Bezzio, C., additional, Principi, M.B., additional, Ribaldone, D.G., additional, Allocca, M., additional, Mocci, G., additional, Bodini, G., additional, Spagnuolo, R., additional, Vernia, P., additional, Mazzuoli, S., additional, Laino, G., additional, Barberio, B., additional, Zerboni, G., additional, Aratari, A., additional, and Papi, C., additional

Published
2019
Full Text
View/download PDF

45. PC.01.4 PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG-IBD STUDY RIDART 1

Author

Bergamaschi, G., primary, Giuffrida, P., additional, D'Incà, R., additional, Lenti, M.V., additional, Astegiano, M., additional, Aronico, N., additional, Fries, W., additional, Rizzello, F., additional, Cococcia, S., additional, Ciacci, C., additional, Bossa, F., additional, Orlando, A., additional, Ghigliazza, G., additional, Castiglione, F., additional, Milla, M., additional, Nardelli, S., additional, Principi, M.B., additional, Scribano, M.L., additional, Ricci, C., additional, Mazzucco, D., additional, Riegler, G., additional, Bassotti, G., additional, Buda, A., additional, Neri, M., additional, Bodini, G., additional, Monica, F., additional, Manca, A., additional, Villa, E., additional, Masotti, M., additional, Comberlato, M., additional, Saimbeni, S., additional, Sidoli, L., additional, Cannatelli, R., additional, Neve, V., additional, Vernia, P., additional, Pieraccini, A., additional, Testa, A., additional, Mengoli, C., additional, Rizzuto, G., additional, Fontana, R., additional, Iovino, P., additional, Valerii, C., additional, Vraca, T. Pinto, additional, Ponzo, E., additional, Caccaro, R., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2019
Full Text
View/download PDF

46. OC.12.1 REAL-LIFE EFFECTIVENESS OF USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CONCOMITANT PSORIASIS OR PSORIATIC ARTHRITIS: AN IG-IBD STUDY

Author

Pugliese, D., primary, Daperno, M., additional, Fiorino, G., additional, Savarino, E., additional, Mosso, E., additional, Biancone, L., additional, Testa, A., additional, Sarpi, L., additional, Cappello, M., additional, Bodini, G., additional, Caprioli, F., additional, Festa, S., additional, Laino, G., additional, Maconi, G., additional, Mazzuoli, S., additional, Mocci, G., additional, Sartini, A., additional, D'Amore, A., additional, Alivernini, S., additional, Gremese, E., additional, and Armuzzi, A., additional

Published
2019
Full Text
View/download PDF

48. P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study

Author

Pugliese, D, primary, Daperno, M, additional, Fiorino, G, additional, Savarino, E, additional, Mosso, E, additional, Biancone, L, additional, Testa, A, additional, Sarpi, L, additional, Cappello, M, additional, Bodini, G, additional, Caprioli, F, additional, Festa, S, additional, Laino, G, additional, Maconi, G, additional, Mazzuoli, S, additional, Mocci, G, additional, Sartini, A, additional, D'Amore, A, additional, Alivernini, S, additional, Gremese, E, additional, and Armuzzi, A, additional

Published
2019
Full Text
View/download PDF

49. P783 Long-term colectomy rate in acute severe ulcerative colitis. An observational multi-centre study on behalf of IG-IBD (Italian group for the study of inflammatory bowel disease)

Author

Festa, S, primary, Scribano, M L, additional, Pugliese, D, additional, Sarli, E, additional, Bezzio, C, additional, Principi, M B, additional, Ribaldone, D G, additional, Allocca, M, additional, Mocci, G, additional, Bodini, G, additional, Spagnuolo, R, additional, Vernia, P, additional, Mazzuoli, S, additional, Laino, G, additional, Barberio, B, additional, Zerboni, G, additional, Aratari, A, additional, and Papi, C, additional

Published
2019
Full Text
View/download PDF

50. P576 Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study

Author

Bertani, L, primary, Bodini, G, additional, Mondello, G, additional, Mumolo, M G, additional, Maltinti, S, additional, Baldissarro, I, additional, Tapete, G, additional, Albano, E, additional, Ceccarelli, L, additional, Crespi, M, additional, Savarino, V, additional, Marchi, S, additional, and Costa, F, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results